Cargando…
Kinase Inhibitors and Ovarian Cancer
Ovarian cancer is fifth in the rankings of cancer deaths among women, and accounts for more deaths than any other gynecological malignancy. Despite some improvement in overall-(OS) and progression-free survival (PFS) following surgery and first-line chemotherapy, there is a need for development of n...
Autores principales: | Katopodis, Periklis, Chudasama, Dimple, Wander, Gurleen, Sales, Louise, Kumar, Juhi, Pandhal, Manreen, Anikin, Vladimir, Chatterjee, Jayanta, Hall, Marcia, Karteris, Emmanouil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770231/ https://www.ncbi.nlm.nih.gov/pubmed/31547471 http://dx.doi.org/10.3390/cancers11091357 |
Ejemplares similares
-
Detection of Abundant Non-Haematopoietic Circulating Cancer-Related Cells in Patients with Advanced Epithelial Ovarian Cancer
por: Kumar, Juhi, et al.
Publicado: (2019) -
Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro
por: Filipe, Alice, et al.
Publicado: (2022) -
Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry
por: Rogers-Broadway, Karly-Rai, et al.
Publicado: (2019) -
Circulating tumour cells and circulating cell-free DNA in patients with lung cancer: a comparison between thoracotomy and video-assisted thoracoscopic surgery
por: Katopodis, Periklis, et al.
Publicado: (2021) -
Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro
por: ROGERS-BROADWAY, KARLY-RAI, et al.
Publicado: (2016)